Strategic partnerships ORB has recently partnered with Boca Biolistics Clinical Reference Laboratory to develop a validated 35-plex cytokine/chemokine immunoassay for companion diagnostics, highlighting a pathway for co-developed tests and expanded service scope with CRO collaborations.

Multi-omics focus The company specializes in RNA and protein-based biomarker discovery across circulating small RNA, exosome characterization, microbiome sequencing, multiplex immunoassays, and DNA polymorphism analysis, enabling a broad menu of assay services for pharma and biotech clients seeking comprehensive biomarker solutions.

Clinical companion potential ORB envisions releasing multi-analyte companion diagnostics alongside client drug launches, presenting a clear opportunity to engage sponsors early in development for integrated diagnostic strategies and value-added testing offerings.

Academic and pharma traction With collaborations involving Emory University, Roosevelt Hospital, and the University of Miami and a publication footprint across 90+ articles, ORB demonstrates established academic and industry credibility favorable for partner-led sales and sponsorship opportunities.

Growth and market positioning Operating in a South Florida Life Science Cluster near a growing ecosystem, ORB is positioned to win business from mid-market biotech and pharma players seeking specialized biomarker services, faster time-to-insight, and scalable lab capabilities at a mid-range revenue bracket.